Brad Johnson Selected Research

Atopic Dermatitis (Atopic Eczema)

2/2024

Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brad Johnson Research Topics

Disease

1	Atopic Dermatitis (Atopic Eczema) 02/2024
1	Pneumothorax 01/2016
1	Critical Illness (Critically Ill) 01/2016
1	Thrombosis (Thrombus) 08/2015
1	Venous Thrombosis (Deep-Vein Thrombosis) 05/2012
1	Pulmonary Embolism 05/2012
1	Infections 09/2005
1	Ichthyosis (Xeroderma) 07/2003

Drug/Important Bio-Agent (IBA)

1	crisaboroleIBA 02/2024
1	Tacrolimus (Prograf)FDA LinkGeneric 02/2024
1	Prostaglandins FIBA 09/2005
1	PolyestersIBA 09/2005
1	SilverIBA 09/2005
1	Anti-Bacterial Agents (Antibiotics)IBA 09/2005
1	EnzymesIBA 07/2003

Therapy/Procedure

2	Catheters 01/2016 - 08/2015
1	Central Venous Catheters 01/2016
1	Resuscitation 01/2016
1	Decompression 08/2015
1	Contraindications 05/2012